INTRODUCTION
Multidrug resistance (MDR) is the leading cause of cancer treatment failure. Members of the ATP-binding cassette (ABC) transporter family mediate cellular efflux to protect tissues from xenobiotics. The xenobiotic receptors, constitutive androstane receptor (CAR) and pregnane X receptor (PXR) regulate the expression of drug-metabolizing enzymes and transporters that contribute to drug resistance. 1 Because of the constitutive activity of CAR, 2 therapies that modulate CAR expression may effectively deter CAR-driven drug resistance.
Drug resistance is regulated in part by microRNAs (miRNAs), 3 which cause direct mRNA cleavage or translational repression via sequence-specific base pairing with the 3 0 untranslated region (UTRs) of target mRNA. 4 miRNAs regulate many biological processes, 5, 6 affect cancer prognosis 7 and may influence response to chemotherapy. 8, 9 The differential expression of miRNAs in drugsensitive versus drug-resistant cells [10] [11] [12] [13] suggests that modulation of miRNA expression may reduce or reverse drug resistance.
Neuroblastoma causes 15% of all childhood cancer-associated mortality.
14 It initially responds well to chemotherapy but frequently recurs in a chemoresistant form. Evidence suggests that chemoresistance increases with increased drug efflux mediated by upregulation of ABC transporters, including MDR1, [15] [16] [17] and epigenetic silencing of tumor suppressor genes through DNA hypermethylation. 18, 19 Identification of additional biomarkers independently associated with survival, and elucidation of their function, may offer greater insight into the underlying biology of the disease and the mechanisms of treatment response and relapse. Although miRNAs have not been extensively implicated in drug resistance in neuroblastoma, several studies have identified miRNAs associated with poor clinical outcome. [20] [21] [22] [23] We investigated the functional relation of miRNAs to CAR, MDR1 (P-glycoprotein) and chemoresistance. miR-137, one of the few miRNAs predicted to target CAR, was selected for study because (1) it is broadly conserved in vertebrates, (2) it is reportedly hypermethylated in cancers and (3) its absence in cancers is associated with reduced survival. [24] [25] [26] [27] [28] CAR expression was greater and miR-137 expression was less in doxorubicin-resistant versussensitive neuroblastoma cells. Further, miR-137 targeted the 3 0 UTR of CAR and negatively regulated CAR expression in neuroblastoma, hepatocellular carcinoma and colon adenocarcinoma cells, identifying CAR as a bona fide target of miR-137. Restoration of miR-137 sensitized doxorubicin-resistant neuroblastoma cells and significantly reduced the growth of doxorubicin-resistant neuro-blastoma xenografts in vivo. Unexpectedly, CAR negatively regulated miR-137 expression and, together with hypermethylation of the miR-137 promoter, reduced miR-137 expression in doxorubicin-resistant neuroblastoma. These findings warrant further investigation of the clinical potential of reducing MDR by manipulating miRNA regulation of CAR.
RESULTS

Inverse relation of miR-137 and CAR levels in neuroblastoma cells
Recent studies have linked cancer drug resistance to altered expression of miRNAs. 11 To investigate the change in miRNA expression in drug-resistant cancer cells, we used the parental (UKF-NB3) neuroblastoma cell line, isolated from bone marrow metastases from N-myc-amplified stage 4 neuroblastoma patients, and its doxorubicin-resistant sub-line, UKF-NB3 r Dox 20 (UKF-NB3/Dox-R) generated by adapting the cells to grow in the presence of doxorubicin (20 ng/ml) as described, 29, 30 as experimental models. In UKF-NB3/Dox-R cells, miR-137 was among the miRNAs dramatically downregulated, whereas CAR mRNA was upregulated with little change in PXR mRNA (Figures 1a  and b) . Western blot analysis indicated greater expression of CAR and of its transcriptional target genes, MDR1, 31 CYP2B6, 32 and to a lesser extent, MCL1, 33 in resistant cells than in parental cells (Figure 1c ). Mcl-1 participates in CAR-mediated anti-apoptotic effects and contributes to doxorubicin resistance. [34] [35] [36] In contrast, levels of doxorubicin-regulated Bcl-X L , Bcl-2 and MMP-1 [37] [38] [39] were not found to differ significantly (Figure 1c ). To determine whether the observed inversely related expression was cell type-specific, we measured CAR mRNA and miR-137 in parental and doxorubicinresistant hepatocellular HepG2 and colon LS174 cancer cells by qRT-PCR. In doxorubicin-resistant cells, expression of miR-137 was lower and that of CAR mRNA was higher than in parental cells (Supplementary Figure 1A , B and C). However, HepG2 and LS174 Figure 1 . Reciprocal expression of miR-137 and CAR in parental and doxorubicin-resistant neuroblastoma. (a) miR-137 expression is downregulated in doxorubicin-resistant cells. The Megaplex Pools for microRNA Expression Analysis (Applied Biosystems Inc) were used for microRNA arrays. miRNA levels are expressed in log scale. (b) miR-137 expression is lower and CAR mRNA expression is higher in UKF-NB3/ Dox-R than in UKF-NB3 cells. QRT-PCR was used to measure levels of miR-137 (left) and CAR mRNA (right). (c) Levels of CAR, MDR1, and CYP2B6 are higher in UKF-NB3/Dox-R cells than in UKF-NB3 cells, whereas levels of doxorubicin-regulated Bcl-X L , Bcl-2 and MMP-1 are similar. b-actin was used as loading control for western blots. In experiments shown in (a) and (b), the miR-137 or CAR level was set to 1 in UKF-NB3 cells. cells expressed significantly greater CAR mRNA and lower miR-137 than UKF-NB3 cells (Supplementary Figure 1B & C) . Taken together, these data suggest that prolonged doxorubicin treatment downregulated miR-137, leading to the upregulation of CAR and its target gene MDR1, and contributed to doxorubicin resistance. miR-137 as a negative regulator of CAR To determine whether elevated CAR levels in doxorubicin-resistant neuroblastoma cells increase the transcriptional activity of CAR, we performed a reporter luciferase assay in UKF-NB3 and UKF-NB3/ Dox-R cells co-transfected with the CAR-regulated CYP2B6 promoter reporter (CYP2B6pro-Luc) 32, 40 and a Renilla luciferase (Rluc) construct (as transfection control) for 48 h. As expected, CYP2B6pro-Luc activity was significantly greater in the doxorubicinresistant cells than in the parental cells (Figure 2a) .
To determine whether miR-137 directly targets the CAR 3 0 UTR, we used reporter assays outlined in Figure 2b . 41 In Assay 1 overexpression of miR-137 significantly downregulated reporter activity of CYP2B6 pro-Luc (Figure 2c ). In Assay 2 we used Figure 2 . miR-137 negatively regulates CAR by directly targeting its 3 0 UTR. (a) CYP2B6pro-Luc activity is higher in UKF-NB3/Dox-R than in UKF-NB3 cells. Luciferase assay was performed 48 h after transfection. The y axis denotes the relative luciferase units (RLU) of CYP2B6pro-Luc (normalized to the co-transfected Renilla luciferase reporter, Rluc). RLU in UKF-NB3/Dox-R was compared with that in UKF-NB3 cells (set to 1) in the Student's t-test. 
pEXZ-CAR 3
0 UTR-luc, which contains the CAR 3 0 UTR cloned directly downstream of the luciferase gene, and Rluc under the control of a CMV promoter as transfection control. The pEXZ-CAR 3 0 UTR-luc construct was co-expressed with pSIF, miR-137 (predicted to target CAR) or miR-514-1 (not predicted to target CAR). miR-137, but not miR-514-1, downregulated the activity of pEXZ-CAR 3 0 UTRluc (Figure 2d ). When mutations that disrupt the binding of CAR 3 0 UTR to the miR-137 'seed' sequence were introduced into pEXZ-CAR 3 0 UTR-luc (to generate CAR 3 0 UTR Mut), the downregulation of luc by miR-137 was abolished (Figure 2e ), indicating that CAR is a bona fide miR-137 target gene. Steady-state CAR mRNA levels were significantly reduced when miR-137 was overexpressed (Figure 2f ), indicating that mRNA degradation likely contributed to miR-137-mediated CAR suppression. As expected, overexpression of miR-137 reduced CAR (both endogenous and exogenously expressed from the pcDNA-CAR-3 0 UTR), CYP2B6, MDR1 and Mcl-1 proteins (Figure 2g ). Furthermore, miR-137 negatively regulated CYP2B6 pro-Luc when co-expressed with a pcDNA-CAR 3 0 UTR construct but not when co-expressed with pcDNA-CAR (lacking the 3 0 UTR) (Figure 2h ), further demonstrating that miR-137 regulation of CAR is CAR-3 0 UTR-dependent. Collectively, these data indicate that miR-137 is a bona fide negative regulator of CAR.
miR-137 downregulates CAR expression and resensitizes doxorubicin-resistant cells to doxorubicin Tumor-suppressive miRNAs generally target oncogenes or repress cell growth-promoting factors. miR-137 is viewed as a tumor suppressor downregulated in cancers. 24, 42, 43 Doxorubicin-resistant neuroblastoma cells expressed a lower level of miR-137 and a higher level of CAR and MDR1 than did parental cells ( Figure 1 ). Doxorubicin is a substrate of MDR1. 44, 45 To test the hypothesis that increased miR-137 reduces levels of CAR to increase intracellular accumulation of doxorubicin and drug sensitivity, we ectopically Doxorubicin reduces Bcl-2 and Bcl-X L to reduce cell proliferation and increase apoptosis; 39, 46 inhibits MMP-1 to reduce cell migration; 37 and downregulates CDC25c to arrest cell cycle progression. 47, 48 Consistent with the intracellular accumulation of doxorubicin ( Figure 3a ) and expression levels of doxorubicinregulated genes (Figure 3b ), miR-137 resensitized doxorubicinresistant cells to doxorubicin treatment, as indicated by decreased cell viability (Figure 3d ), increased activation of caspase 3/7, apoptosis and G2 cell cycle arrest (Figures 3e-g ), and reduced cell migration (Figure 3h ), all of which were rescued by ectopically expressed CAR (pcDNA-CAR lacking the 3 0 UTR). Similar results were observed in doxorubicin-resistant HepG2 and LS174T cells (Supplementary Figure 2 ; cell migration assay not performed), indicating that the effect of miR-137 on doxorubicin resistance is not tumor type-specific and that miR-137 may reverse CAR-driven drug resistance in tumor cells by increasing intracellular accumulation of doxorubicin.
To further confirm that the overexpressed CAR was functional and could be modulated, we showed that the CAR inverse agonist clotrimazole decreased, whereas the CAR agonist CITCO increased, CYP2B6 promoter activity ( Figure 4a ) and endogenous MDR1 and CYP2B6 mRNA levels ( Figure 4b ). In addition, in a chromatin immunoprecipitation (ChIP) assay, CAR bound to CYP2B6 promoter, and this binding was decreased when miR-137 was ectopically expressed (Figure 4c ). IgG and anti-RNA polymerase II were used as nonspecific negative and positive controls, respectively, in the ChIP assay. To further confirm the inverse relation between miR-137 level and CAR, we used anti-miR-137 (antisense oligonucleotides harboring complementary reverse sequences of miR-137 expressed from a plasmid) to reduce the level of endogenous miR-137, which increased the level of CAR mRNA ( Figure 4d ) and CAR, MDR1, and CYP2B6 protein ( Figure 4e ) in doxorubicin-sensitive neuroblastoma cells (which possess higher levels of endogenous miR-137). Anti-miR-137 also reduced the doxorubicin sensitivity of UKF-NB3 cells, as measured by cell viability and caspase 3/7 activation (Figures 4f and g ). CITCO, clotrimazole and anti-miR-137 produced similar effects in colorectal adenocarcinoma cells (Supplementary Figure 3) . Collectively, our findings showed that the overexpressed CAR in doxorubicin-resistant cells is functional and that increasing levels of miR-137 reduce CAR and MDR1 levels, increase intracellular accumulation of doxorubicin and resensitize the doxorubicin-resistant cells.
CAR and miR-137 form a negative feedback loop and hypermethylation of the miR-137 promoter contributes to reduced miR-137 expression in doxorubicin-resistant cells CAR is involved in both transcriptional activation and transcriptional repression. 49 To determine whether CAR contributes to reduced miR-137 expression in UKF-NB3/Dox-R cells, we performed qRT-PCR after overexpression of CAR. Exogenously expressed CAR led to reduced miR-137 expression (Figure 5a ). Of the two putative promoters that might regulate the expression of Figure 4) , suggesting that CAR represses miR-137 expression at the proximal promoter. For confirmation, we cloned the miR-137 promoter into the pGL4.20 vector directly upstream of the luciferase gene (miR-137pro-Luc) and co-expressed this construct with pcDNA-CAR plasmid. We found significantly less miR-137pro-Luc activity in cells expressing CAR than in those expressing pcDNA3.1 þ (Figure 5b ). To determine whether CAR repression of the miR-137 promoter is compromised by ectopically expressed miR-137, we examined the activity of miR-137pro-Luc in HepG2 cells co-transfected with pSIF or miR-137 and pcDNA-CAR or pcDNA-CAR-3 0 UTR. miR-137pro-Luc activity increased in cells co-transfected with miR-137 and pcDNA-CAR-3 0 UTR but not in miR-137, CAR, MDR1 and sensitivity to doxorubicin AA Takwi et al 0 UTR inhibition of miR-137 promoter (miR137pro-Luc) activity (top), but not of pcDNA-CAR (bottom), is rescued by miR-137 overexpression (activity from miR-137 was compared to that from pSIF in the Student's t test). (d) Methylation-specific PCR shows greater methylation of the miRNA-137 promoter in doxorubicin-resistant than in doxorubicin-sensitive neuroblastoma cells. Primers for fully methylated and fully demethylated alleles of the promoter were used to amplify bisulfite-converted genomic DNA. Top: a representative gel. Band intensity was quantified by using ImageJ software. Bottom: values on bar graph represent the mean and SD of three samples. AU (arbitrary unit) from UKF-NB3/Dox-R was compared with that from UKF-NB3 cells in the Student's t-test. (e and f ) UKF-NB3/Dox-R cells were treated for 72 h with 2.5 mM 5-azacytidine (Sigma), alone or together with 0.5 mM doxorubicin. Drug and medium were replaced every 24 h, followed by qRT-PCR (e) and western blot analysis (f ). *Pp0.05. Several studies have shown downregulation of miR-137 in various tumors, 24, 42, 43 and hypermethylation at the miR-137 promoter contributes to the downregulation. [24] [25] [26] We performed methylation-specific PCR of the miR-137 promoters and found that the promoters were more methylated in UKF-NB3/Dox-R cells than in UKF-NB3 cells (Figure 5d ), suggesting that methylation contributes to the reduced miR-137 expression in these cells. In miR-137, CAR, MDR1 and sensitivity to doxorubicin AA Takwi et al UKF-NB3/Dox-R cells cultured in doxorubicin, methylation inhibitor 5-azacytidine (72 h treatment) increased miR-137 expression, reduced CAR mRNA (Figure 5e ) and reduced protein levels of CAR, MDR and CYP2B6 (Figure 5f ).
Collectively, these data indicate a negative feedback loop between miR-137 and CAR, wherein CAR negatively regulates miR-137 expression and miR-137 negatively regulates CAR expression. Increased methylation of the miR-137 promoter also contributes to the lower miR-137 expression in doxorubicin-resistant cells. Therefore, miR-137 promoter hypermethylation and CAR overexpression contribute to the downregulation of miR-137 in doxorubicin-resistant neuroblastoma cells. miR-137 reduces growth of doxorubicin-resistant neuroblastoma xenografts Soft-agar colony formation assays are routinely used to detect anchorage-independent growth (a hallmark of cell transformation). We used this assay to investigate whether miR-137-sensitization of doxorubicin-resistant cells was sufficient to reduce their transformation capability. UKF-NB3 and UKF-NB3/Dox-R cells stably expressing pSIF or miR-137 ( Figure 6a ) were incubated in soft agar for 2 weeks, with vehicle or doxorubicin treatment every 72 h. Without doxorubicin, the two cell lines formed colonies of similar number and size, regardless of miR-137overexpression (Figure 6b ). With doxorubicin treatment, pSIF-and miR-137-expressing doxorubicin-sensitive UKF-NB3 cells formed smaller and fewer colonies (smallest in miR-137-expressing cells). Significantly, miR-137-expressing UKF-NB3/Dox-R cells formed smaller and fewer colonies with doxorubicin treatment than did pSIF-expressing cells (Figure 6b ). Exogenous overexpression of CAR rescued the reduced colony formation, indicating that this reduction was CAR-dependent (Figure 6b) .
We next used a subcutaneous xenograft model to determine whether miR-137 reduces the growth of doxorubicin-treated UKF-NB3/Dox-R tumors in vivo. The growth rate of the doxorubicin-sensitive tumor cells was reduced by doxorubicin irrespective of miR-137 expression (Figure 6c ). In contrast, the growth rate of UKF-NB3/Dox-R xenografts was reduced by doxorubicin only when miR-137 was expressed (Figure 6c ). MDR1 levels were reduced in all xenografts in which miR-137 was expressed, regardless of doxorubicin treatment (Figure 6d ). In UKF-NB3 xenografts, doxorubicin treatment led to higher levels of cleaved caspase 3, irrespective of miR-137 expression. However, in UKF-NB3/Dox-R xenografts, doxorubicin treatment increased levels of cleaved caspase 3 only when miR-137 was expressed (Figure 6d ). qRT-PCR confirmed the higher expression of miR-137 from miR-137-expressing tumors (Figure 6e and Supplementary Figure 5A ) and the inversely related CAR mRNA levels (Figure 6f and Supplementary Figure 5B) . Together, these results indicated that the miR-137 level is crucial to the response of neuroblastoma to doxorubicin.
DISCUSSION
Here, we showed that expression of CAR and its target, MDR1, is higher in doxorubicin-resistant neuroblastoma cells than in their doxorubicin-sensitive parental cells, whereas PXR shows no change. This finding suggests that CAR, reported to be overexpressed in various other cancers, drives doxorubicin resistance via upregulation of MDR1. We showed that negative regulators of CAR, such as miR-137, can reduce CAR-mediated drug resistance.
Evidence increasingly suggests that epigenetic changes have a crucial role in the development and progression of human malignancies. 50 Altered expression of miRNAs, a common feature of malignancies, 51, 52 has recently been linked to epigenetic mechanisms. 53 Methylation of the CpG island of miR-137 has been discovered in oral, 27 colon 24, 25 and gastric 26 cancers, associated with poorer survival in head and neck squamous cell carcinoma, 28 and detected in oral rinses from these patients, suggesting its utility as a cancer biomarker. 54 Balaguer et al.
24
showed that miR-137 is epigenetically regulated in colorectal cancer and that reduced expression contributes to colorectal carcinogenesis. miR-137 is considered to act as a tumor suppressor by targeting pro-survival genes such as those encoding CDK6, MITF, 42 CDC42 43 and ERRa. 55 We showed that increased methylation of the miR-137 promoter contributes to reduced miR-137 expression in doxorubicin-resistant cells. Further, treatment of doxorubicin-resistant cells with the methylation inhibitor 5-azacytidine resulted in the upregulation of miR-137 expression. We also found that CAR negatively regulates miR-137. Our findings demonstrate that CAR overexpression contributes to reduced miR-137 expression. Therefore, we have shown for the first time a negative feedback loop between CAR and miR-137, wherein each negatively regulates the other.
Downregulation of CAR by miR-137 reduced expression of MDR1, suggesting that levels of miR-137 may affect intracellular drug levels. We found that intracellular doxorubicin levels were higher in miR-137-expressing than in pSIF-expressing cells, resulting in decreased expression of doxorubicin-regulated proteins (for example, Bcl-2, Bcl-X L , MMP-1 and CDC25c) and increased sensitivity of doxorubicin-resistant cells to doxorubicin, as evidenced by increased G2 cell cycle arrest, caspase 3/7 activity and apoptosis and decreased cell proliferation. Overexpression of miR-137 significantly increased the doxorubicin-mediated growth inhibition of xenografts in mice. The effect of miR-137 on doxorubicin-resistant neuroblastoma cells was not tumor-specific, as results were similar in doxorubicin-resistant colon cancer (LS174) and hepatocellular cancer (HepG2) cell lines.
We observed lower expression of miR-137 and greater reciprocal expression of CAR and MDR1 in doxorubicin-resistant cells than in parental cells. Multiple studies have shown miR-137 to act as a tumor suppressor whose promoter is hypermethylated in cancer, [24] [25] [26] [27] [28] suggesting that miR-137 might have a role in carcinogenesis. We have demonstrated for the first time that miR-137, CAR, MDR1 and sensitivity to doxorubicin AA Takwi et al epigenetic silencing of an miRNA (miR-137) in doxorubicin-resistant cells contributes to the overexpression of CAR and, in turn, MDR1. miR-137, which negatively regulates CAR (and in turn MDR1 and CYP2B6), sensitized doxorubicin-resistant cells to doxorubicin. Downregulation of MDR1 and CYP2B6 increased the intracellular doxorubicin levels, enhancing the therapeutic effect of doxorubicin. We also report for the first time a negative feedback loop between CAR and miR-137, in which one negatively regulates the expression of the other. Collectively, our results suggest a novel therapeutic possibility: incorporation of a miRNA into combination chemotherapy to reduce drug efflux in cancers that develop CARmediated drug resistance. Synthetic miRNAs (miR mimetics) can mimic the endogenous functions of an miRNA but have not yet demonstrated in vivo efficacy because of low stability and poor cellular delivery. [56] [57] [58] [59] Alternative approaches to increase the expression of endogenous miRNA, including the use of small molecules, 41, 60 should be explored to further validate this therapeutic concept. Figure 7 summarizes the functional miR-137, CAR, MDR1 and sensitivity to doxorubicin AA Takwi et al relationships of miR-137, CAR, MDR1 and cellular drug sensitivity revealed by our findings.
MATERIALS AND METHODS
Cell culture, transfection and transduction
Cells were cultured at 37 1C in 5% CO 2 . 293T, HepG2 and LS174 (ATCC, Manassas, VA, USA) were cultured according to ATCC guidelines. UKF-NB3 and UKF-NB3/Dox-R were cultured as previously described. 29, [61] [62] [63] The doxorubicin-resistant HepG2 and LS174 cells (HepG2/Dox-R, LS174/ Dox-R) were generated by adapting the cells to doxorubicin (20 ng/ml) for 4-6 months in essential modified Eagle's medium (ATCC) supplemented with 10% fetal bovine serum and 0.1% (v/v) antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA, USA).
Lipofectamine LTX (Invitrogen) or Fugene 6 (Promega; Madison, WI, USA) was used for transient transfection. Dual luciferase assays were performed as previously described. 64 miRNAs were stably expressed by transduction with lentivirus carrying the MIR137 gene or the pSIF control vector. 41 Molecular cloning and assays 
MicroRNA array and quantitative real-time PCR
We used the Megaplex Pools for microRNA Expression Analysis (Applied Biosystems Inc., Foster City, CA, USA) to compare miRNA expression among cell lines. cDNA, generated by RT-PCR, was analyzed on an H7900-cycle 384-well TaqMan Low Density Array. Data were analyzed by using the Qiagen DataAssist software (Qiagen, Valencia, CA, USA), arbitrarily assigning a value of 1.0 to expression levels in parental cells. We used TaqMan assays (Applied Biosystems Inc.) to measure expression of mature miRNAs and CAR mRNA, using U6 RNA and b-actin mRNA as respective references. 65 Total RNA (0.1 mg) was generated from cells or xenograft samples by using the Maxwell 16LEV simplyRNA tissue kit (Promega).
Methylation-specific PCR DNA was extracted from cells with the DNeasy Blood and Tissue Kit (Qiagen) and treated with sodium bisulfite using the Qiagen Plus DNA Bisulfite Kit. Methylated MIR137 promoter was amplified by methylation-specific PCR and separated on a 4% agarose gel. The primer sequences were: 5 0 -GCGGTAGTAGTAGCGGTAGC-3 0 and 5 0 -ACCCGTCACCG AAAAAAA-3 0 (for methylated alleles); 5 0 -GGTGGTAGTAGTAGTGGTAGT-3 0 and 5 0 -TACCCATCACCAAAAAAAA-3 0 (for unmethylated alleles) (expected amplicon, 86 bp each). 54 Fully methylated and unmethylated bisulfiteconverted human DNAs (Qiagen) were used as positive and negative controls. Band intensity was measured by using ImageJ software. Three samples were analyzed per cell line. Doxorubicin intracellular uptake assay UKF-NB3 and UKF-NB3/Dox-R cells stably expressing pSIF-or miR-137 (1 Â 10 6 /well) were seeded into six-well plates, incubated with DMSO or 0.5 mM doxorubicin for 6 h at 37 1C, washed twice with FACS buffer, and resuspended in FACS buffer (0.5% bovine serum albumin in PBS). The intrinsic fluorescence of intracellular doxorubicin 66 was excited with an argon laser at 488 nm and emission was read in an LSR II Flow Cytometer (BD Biosciences, San Jose, CA, USA), using a 620-nm filter. 67, 68 Histograms were generated using FlowJo 10 software (Tree Star, Ashland, OR, USA), and each included a minimum of 200 000 living cells.
ChIP assay UKF-NB3 and UKF-NB3/Dox-R cells stably expressing pSIF-or miR-137 and plated in 10-mm dishes were crosslinked and processed as previously described. 69 Precleared chromatin solution was incubated overnight at miR-137, CAR, MDR1 and sensitivity to doxorubicin AA Takwi et al 4 1C with 5 mg of anti-hCAR (Perseus Proteomics, Tokyo, Japan), anti-RNA Pol II (positive control) or normal rabbit IgG (Santa Cruz Biotechnology; negative control). Immunoprecipitates were collected and DNA was purified by using a DNeasy Blood and Tissue kit (QIAGEN). The PBREM region of the CYP2B6 promoter was amplified by the SYBR green method, using the purified DNA as template and the primers CYP2B6-F: 5 0 -CTGCA ATGAGCACCCAATCTT-3 0 and CYP2B6-R: 5 0 -ACACATCCTCTGACAGGGTC A-3 0 , as previously described. 70 
Cellular assays
To determine whether miR-137 targets the 3 0 UTR of CAR, cells were co-transfected with pEZX-CAR 3'UTR (wild-type or mutated at the miR-137 'seed' binding region) and pSIF, miR-137 or miR-514-1 for 48 h in 96-well plates, and the Dual-Glo luciferase assay (Promega) was performed. Values were normalized to pSIF control. CAR transcriptional activity was determined similarly after co-transfection of cells with a CYP2B6 promoter-luciferase construct (CYP2B6pro-Luc), CMV-Rluc, pcDNA-CAR or pcDNA-CAR-3 0 UTR and pSIF or miR-137 for 48 h. The effect of miR-137 on endogenous CAR activity was assessed in UKF-NB3 and UKF-NB3/Dox-R cells co-transfected for 48 h with CYP2B6pro-Luc, CMV-Rluc and pSIF or miR-137. To determine whether CAR regulates the miR-137 promoter, cells were co-transfected for 48 h with pSIF or miR-137; pcDNA-CAR, or pcDNA-CAR-3 0 UTR; and pGL4.20 or pGL4.20-miR-137pro-Luc. Luminescence was read on an Envision Multilabel Plate Reader (Perkin Elmer; Waltham, MA, USA).
Cell proliferation was assessed by using the Cell Titer Glo assay (Promega). Apoptosis was measured by using the Annexin V apoptosis assay (Miltenyi Biotec; Auburn, CA, USA) in six-well format and the Caspase Glo 3/7 kit (Promega) in a 96-well format. Cells were transfected in 96-well plates with pSIF or miR-137 with or without pcDNA-CAR and treated with vehicle or 0.5 mM doxorubicin for 72 h and 24 h, respectively, before the assays. Similar assays were performed after transfection of cells with an antisense miR-137 plasmid or a scrambled antisense control.
Cell migration was assayed in Matrigel-coated transwell chambers (BD Biosciences) with 8-mm pores, reconstituted with fresh medium for 2 h. Cells (2 Â 10 4 ml À 1 in 0.5 ml serum-free MEM in 12-well plates) were added to the upper chambers, and 1 ml MEM supplemented with 10% fetal bovine serum was placed in the lower chamber. After 24 h, cells were fixed with 70% ethanol and stained with 0.4% crystal violet for 2 h. Nonmigrating cells were removed with a cotton swab from the upper side of the filter. The filter was mounted on a glass microscope slide, and cells were quantified by using ImageJ software. Results were expressed as the mean number of migrated cells normalized to the number of live cells cultured in parallel. Cell cycle analysis was performed as previously described. 71 Soft-agar colony-formation assay Two thousand viable cells in 1.5 ml of culture medium containing 1% glutamine, antibiotics and 0.2% soft agar were layered on 0.5% solidified agar in IMDM culture medium in six-well plates, incubated at 37 1C for 2 weeks and stained with MTT reagent. Colony foci were counted by light microscopy (magnification Â 4). Experiments were performed in triplicate.
Mouse xenografts and immunohistochemical analyses
All animal experiments were approved by the St Jude Institutional Animal Care and Use Committee. Male (B6-week old) immunodeficient NCr nude mice (Taconic Farms, Hudson, NY, USA) (five per group) were inoculated subcutaneously with 1 Â 10 6 cells in 200 ml of 1 Â PBS. After 2 weeks, animals were randomly divided into two groups per cell line. Mice were injected intraperitoneally with doxorubicin hydrochloride (carboxylate form; Sigma) 0.5 mg/kg or with vehicle three times weekly for 2 weeks. Tumor volume (maximal length Â width Â height) was measured every 2 days.
The LabVision 720 IHC Stainer (ThermoShandon, Fremont, CA, USA) was used for immunohistochemical analysis of tumor tissue. Tissue samples on slides were incubated for 120 min with primary antibodies (anti-MDR1 (sc-55510), Santa Cruz Biotechnology, 1:100; or anti-cleaved caspase 3 (CP229C); BioCare Medicinal, Concord, CA, USA; 1:100) and then for 30 min with secondary antibodies (rodent anti-mouse, rodent anti-rabbit (BioCare Medical; RMR622L), donkey anti-goat polymer-HRP (Santa Cruz Biotechnology; SC-2042) and Quanto mouse on mouse-HRP (Thermo Fisher, Fremont, CA, USA; TL-060-QHDM]). The stained slides were counterstained with DAB chromogen and hematoxylin (ThermoShandon), evaluated histologically for proteins of interest by two independent, blinded observers, and scored according to the intensity of staining (0, negative; 1, weak; 2, moderate; 3, strong).
Statistical analysis
Results were expressed as the mean ± standard deviation of at least three independent experiments. Sample and control values were compared as indicated in the figure legends by using the two-tailed Student's t-test, and Pp0.05 (* or #) was considered statistically significant.
